QuantHealth is a technology company.
QuantHealth has raised $15.0M across 1 funding round.
QuantHealth has raised $15.0M in total across 1 funding round.
QuantHealth has raised $15.0M in total across 1 funding round.
QuantHealth's investors include Michal Drayman, Pitango Venture Capital.
QuantHealth is an AI-powered platform that simulates clinical trials to accelerate and de-risk drug development for pharmaceutical and biotechnology companies.[1][2][3] It serves clinical development and operations teams by predicting patient responses, endpoint success, commercial viability, and protocol feasibility across thousands of trial variations, using data from over 350 million patients, 100,000 drugs, and 1 trillion data points.[3][4][5] The platform solves high failure rates in clinical trials—often exceeding 90% in Phases II and III—by enabling faster decisions on trial design, go/no-go calls, drug repurposing, indication selection, and asset valuation, with reported accuracies of 85-90% and savings like $31.4 million for a top-10 pharma and $215 million overall.[3][6][7] Growth momentum includes simulating over 350 trials across 23-45 therapeutic areas (e.g., oncology, immunology), partnerships with five of the top 20 pharma companies, and launches like the Large Real-World Drug Model (LRDM v1.0).[3][7]
Founded in 2020 and based in Tel Aviv-Yafo, Israel, QuantHealth emerged amid the AI boom in life sciences to tackle inefficiencies in drug development.[2] While specific founders are not detailed in available sources, the company quickly gained traction by building a proprietary engine trained on vast real-world data, including a knowledge graph with over 5 million datapoints mapping biological cascades from therapeutics to diseases.[1][4] Pivotal early moments include simulating over 100 trials with 85% accuracy by 2024, delivering $215 million in savings, and expanding to 350+ trials by mid-2025 with 90% accuracy across diverse areas, alongside partnerships with top pharma firms.[3][6][7]
QuantHealth rides the AI-in-healthcare wave, leveraging foundation models and real-world evidence (RWE) to address the $2.6 billion average cost and 90% failure rate of drug development.[3][6] Timing is ideal post-2020 AI advancements and regulatory shifts toward synthetic data (e.g., FDA pilots), amid market forces like rising trial costs, talent shortages, and demand for precision medicine in oncology and immunology.[2][3] It influences the ecosystem by partnering with top pharmas, enabling faster therapies to 350M+ lives, and competing with firms like Argon AI or BioMap while setting benchmarks for simulation accuracy that could standardize AI in ClinDev.[2][3][7]
QuantHealth is poised to dominate AI-driven clinical simulation, with LRDM v1.1 expansions, doubled pharma partnerships, and more drugs simulated amid growing RWE adoption.[3] Trends like multimodal AI, regulatory acceptance of digital twins, and personalized medicine will propel it, potentially evolving from simulator to full drug discovery partner. As AI reshapes the $1.5 trillion pharma R&D spend, QuantHealth's platform positions it to save billions while hastening breakthroughs, building on its trajectory from Tel Aviv startup to industry essential.
QuantHealth has raised $15.0M across 1 funding round. Most recently, it raised $15.0M Series A in August 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2023 | $15.0M Series A | Michal Drayman, Pitango Venture Capital |